Resultado da Busca
Thomas Pike is Chairman and Chief Executive Officer of Fortrea (Nasdaq: FTRE). He has served in this position since Fortrea’s launch as an independent company in July 2023. Tom joined the organization as President and Chief Executive Officer in January 2023 during Fortrea’s spinoff from its parent company, Labcorp (NYSE: LH).
Thomas Pike is Chairman and Chief Executive Officer of Fortrea (Nasdaq: FTRE). He has served in this position since Fortrea’s launch as an independent company in July 2023.
While CEO of Quintiles, he was a thought leader on improving clinical research, leadership, and other topics. Thomas retired late in 2016 after the company merged with IMS Health. Prior to ...
- 53 min
- 1615
- Stanford Medicine
Marshal of the Royal Air Force Sir Thomas Geoffrey Pike, GCB, CBE, DFC & Bar, DL (29 June 1906 – 1 June 1983) was a senior officer in the Royal Air Force. He served in the Second World War as a night fighter squadron commander and then as a station commander.
5 de jan. de 2023 · Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023.
5 de jan. de 2023 · Thomas (Tom) Pike, an industry veteran, has been named president and CEO of the drug and clinical development business. He will begin on Jan. 9 and report to Labcorp CEO and Chairman Adam...
5 de jan. de 2023 · Tom Pike, the former CEO of Quintiles when the life science giant merged with IMS seven years ago to form the global firm now known as Iqvia, is joining Labcorp to help lead a spinoff. WRAL.com...
